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To date, putative prognostic biomarkers have shown limited utility from the clinical perspec-
tive for bladder urothelial carcinoma. Herein, the expression of beta-tubulin-3 and c-Myc
was evaluated to determine their prognostic potential.
Methods
In formalin fixed-paraffin embedded blocks, immunohistochemical expression of c-Myc and
beta-tubulin-3 was evaluated. H score ranging from 0 to 300 was obtained by multiplying
the percentage of positive cells by intensity (0–3); c-Myc and beta-tubulin-3 expression was
defined: 0: negative, 1: weakly positive, 2: strongly positive.
Results
beta-tubulin-3 and c-Myc immunoexpression was available for 46 cases. At the univariate
analysis, node-involvement, beta-tubulin-3 and c-Myc overexpression discriminate shorter
DFS (HR 2.19, p = 0.043; HR 3.10, p = 0.24 and HR 3.05, p = 0.011, respectively); 2-yrs
DFS log-rank analysis according to low versus high level of immunoexpression were statis-
tically significant; beta-tubulin-3, 53% low vs 12.7% high (p = value 0.02) and c-Myc 28 low
vs 8 high (p-value 0.007). Patients displaying negative beta-tubulin-3/c-Myc had statistically
significant better 2-yrs DFS than those with mixed expression or double positivity (54.5%
versus 18.7% versus 0%, log-rank p = 0.006).
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Conclusions
c-Myc and beta-tubulin-3 show improvement for prognostic risk stratification in patients with
muscle invasive bladder urothelial carcinoma. These molecular pathways may also be can-
didate to improve predictiveness to targeted therapies.
Introduction
Urothelial carcinoma is the 5th most common cancer in industrialized countries, accounting
for approximately 5% of all cancers and represents the second most common genitourinary
malignancy [1,2]. At the time of diagnosis, approximately 70% of patients present with superfi-
cial disease and the remaining 30% with carcinoma infiltrating the muscolaris tonaca. Of this
group about one third of the patients present with metastatic disease not visible at the time of
treatment of the primary tumor. Moreover, approximately 50% of patients undergoing radical
cystectomy for invasive bladder cancer develops a local recurrence or distant, while roughly
10%-15% is presented with metastatic disease at diagnosis.
Currently there are no valid tissue-based biomarkers that serve as useful molecular prognos-
tic factors to guide the clinical management of the patient with carcinoma of the bladder [3,4].
The most crucial treatment decisions are based on clinical risk factors and histopathological
criteria. Overall, the management of these patients may derive great benefit from the identifica-
tion and use of markers reproducible and objective, able to predict the risk of relapse and pro-
gression, thus allowing individualization of treatment. In addition, to reduce the recurrence
rate, limit the progression of superficial disease and increase survival and quality of life of pa-
tients with invasive or metastatic disease, would prove useful new therapeutic approaches to be
used alone or in combination with conventional treatment.
In different districts, overexpression of beta-tubulin-3 in cancer cells has been associated
with resistance to docetaxel-based chemotherapy in patients with advanced cancer [5,6] and
recent inhibitors targeting the c-Myc pathways has been proposed.
Aim of our study was Digita il testo o l'indirizzo di un sito web oppure to evaluate the corre-
lation between these pathways (c-Myc and beta-tubulin-3) and Disease Free Survival (DSF)
(defined as the time from diagnosis to the first observation of disease progression or death
from any type of case) in order to improve a more appropriate stratification of patients with
urothelial carcinoma in advanced stage and a customization of treatment.
Materials and Methods
Ethic Statements
We used tissue samples from human participants. All tissue blocks have been previously
declaired to be available for the purposes of the actual study by the Istitutional Review Board.
This study was conducted according to the Declaration of Helsinki. The study was approved by
the University Hospital of Verona Institutional Review Board (S1 File), approval number n.23/
2013. Tissue blocks used in this study were collected as a part of routine care, and all donors
provided written informed consent.
The full name of the ethics committee/Institutional Review Board: University Hospital of
Verona Institutional Review Board.
The samples analyzed from the 74 patients exist before the study began and were collected
for routine care by MB and GM.
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All co-authors have access to any patient identifying information.
Patients and samples
Patients previously resected for muscle-invasive or metastatic urothelial carcinoma at the De-
partment of Pathology the University Hospital of Verona from 1995 to 2012, whose paraffin
blocks were available for the study, were considered eligible. Only 40 of 46 patients (87%) were
treated with chemotherapy: 34 patients (74%) with cisplatin 70 mg/m2 ev on day 2 plus gemci-
tabine 1000 mg/mq ev on days 1,8,15 every 28 days; 6 patients (13%) with carboplatin AUC 5
on day 1 plus gemcitabine on days 1,8 every 21 days due to a non optimal renal function; 6 pa-
tients (13%) were defined unfit for chemotherapy. A revision of the histological preparations
with regard to the pathological grading and staging was accomplished. Formalin fixed-paraffin
embedded blocks from bladder urothelial carcinomas were retrospectively retrieved from the
archives and 3 tissue microarrays (TMA) were built.
Tissue microarrays (TMA)
Each tumor was sampled 3 times and paired with normal urothelium. The whole slides were re-
viewed and appropiate tumour points were selected for each case in order to build representa-
tive tissue microarray paraffin master blocks. Three cores of neoplastic tissue and two cores of
normal urothelium adjacent were available for each case of muscle invasive urothelial carcino-
ma. We performed three samples for each piece per lymph node metastases, in cases with
lymph node metastasis, histologically diagnosed.
Immunohistochemical analysis
Immunohistochemical expression of c-Myc (Y69, 1:300, Epitomics, Burlingame) and beta-tu-
bulin-3 (3F3, 1:40000, Seven Hills, Bioreagents, Cincinnati) was evaluated. All the sections
were developed with the Envision peroxidase detection system (DAKO, Carpinteria, CA), a
technique very sensitive and capable of preventing false positivity due to endogenous biotin
present in the tissues. The c-Myc was considered positive when expressed at the nuclear level
and classified into three groups: 0 (negative), 1 + (>15% weakly positive cells), 2 + (>15%
strongly positive cells) (Fig 1). The beta-tubulin-3 was considered positive when expressed at
the level membranous and cytoplasmic as follows: 0 (negative), 1 + (>15% weakly positive
cells), 2 + (>15% strongly positive cells) (Fig 2). For beta-tubulin-3, we have also reported a
positive score in the reactive tissue adjacent to the tumor. In order to simplify the results and
choose a single representative value for each variable, we reported the median of the number of
observations corresponding to each patient. The median score per case was used for the
statistical analysis.
Statistics
Descriptive statistics was used to summarize pertinent study information. Follow-up was ana-
lyzed and reported according to Shuster [7]. The correlation between variables were analyzed
according to chi-square, Student's t, and Mann–Whitney (nonparametric) tests. The hazard
ratio (HR) and the 95% confidence intervals (95% CI) were estimated for each variable using
the Cox univariate model [8,9]. A multivariate Cox proportional hazard model was developed
using stepwise regression (forward selection, enter/remove limits P = 0.10 and P = 0.15), to
identify independent predictors of outcomes. The assessment of interactions between signifi-
cant investigation variables was taken into account when developing the multivariate model.
Event-free survival (EFS) and overall survival (OS) were calculated by the Kaplan–Meier
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product limit method from the date of the surgery until death due to cancer or death for any
cause [10]. The log-rank test was used to assess differences between subgroups. Significance
was defined at the p<0.05 level. The SPSS (18.0), and MedCalc (10.0.1) licenced statistical pro-
grams were used for all analyses.
Results
Clinico-pathological findings
The clinico-pathological data of the included 74 patients are summarized in Table 1. Median
age was 67 years (range 44–86). Histological samples from 52 of the 74 patients was recovered
in the context of 9 biopsies (17.3%) and 43 surgical specimens (82.7%) of radical cystectomies
and available for subsequent analysis. Of the 52 series of slides reviewed, those belonging to 4
patients were found for the quality and quantity of material not sufficient to the study and
therefore excluded from the subsequent analysis.
Fig 1. A] c-Myc iperexpression (2+); B] absence of expression of c-Myc.
doi:10.1371/journal.pone.0127908.g001
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Tissue microarray (TMA) master blocks
Three mDigita il testo o l'indirizzo di un sito web oppure aster TMAs comprising 287 cores
were obtained, 177 of which taken from tumor tissue, 76 from normal urothelium adjacent to
the tumor and 34 controls. Of the 177 cores, 33 samples from lymph node metastases were
punched from 11 of 48 patients.
Immunophenotypical profiling
Overall, 46 patients for c-Myc and beta-tubulin-3 were available for final score as the micro-
scopic evaluation of cores from 2 of the 48 patients, originally selected truly were representative
of normal/dysplatic urothelial tissue (the other two cases were lost materials during tissue sec-
tioning). Among 46 cancer, 36 showed usual urothelial, 2 squamous, 2 sarcomatoid, 2 micropa-
pillary, 1 squamo-glandular, 1 small cell, 1 nested, 1 plasmocytoid differentiation. A total of 10
lymph nodes were finally available, as sampling by 1 of the 11 lymph nodes were composed by
whole normal lymphoid tissue. The analysis of lymph node metastasis has detected the preva-
lence of negative cases (6/10 cases, 60%) compared with the positive (1/10 cases of weak posi-
tivity, 10%; 3/10 cases of strong positivity, 30%) with a discrepancy of expression of the marker
in 4 of 10 cases (40%): 1 case is shifted from negative to positive, and 3 cases from weak positive
(weak 1 and strong 2) to negative. c-Myc was positive in 17 cases out of 46 (37%), 13 of these
Fig 2. A] strong positive beta-3-tubulin expression versus absence cores B) 2+ beta-3-tubulin
expression.
doi:10.1371/journal.pone.0127908.g002
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showed a weak positivity (28%) and 4 a strong positivity (8%), while 29 of 46 cases were nega-
tive (63%). Lymph node metastases were strongly positive in 20% of cases (2/10), weakly posi-
tive in 20% (2/10) and negative in the remaining cases (6/10, 60%). In 5 patients it was possible
Table 1. Patients’ characteristics, according to clinicopathological andmolecular variables.







































G: grade; TUR: trans-urethral resection; IHC: immunohistochemistry. Among 46 cancer, 36 showed
urothelial, 2 squamous, 2 sarcomatoid, 2 micropapillary, 1 squamo-glandular, 1 small cell, 1 nested, 1
plasmocytoid differentiation.
doi:10.1371/journal.pone.0127908.t001
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to observe a discrepancy between the expression levels of c-Myc in the primary tumor and
those in lymph nodal metastasis: in 2 cases the strong expression turned from negative to posi-
tive, in 2 cases from negative to weak positive and in 1 case from weak positive to negative. The
expression of beta-tubulin-3 was strongly positive in 17 cases out of 46 (37%), weakly positive
in 15 cases out of 46 (33%) and negative in 14 cases out of 46 (30%). The nodal positivity was
instead found in 4 of 10 cases (40%), while the remaining are negative in 50% of cases (5/10)
and weak in 10% (1/10). Even for the expression of this marker were found some discrepancies
between the primary tumor and lymph node metastasis: in 2 cases the expression shifted from
negative to positive, and in 1 case from positive to negative.
Data analysis
At the univariate analysis, node-involvement, c-Myc and beta-tubulin-3 overexpression dem-
onstrated to discriminate patients for a shorter EFS and OS (Tables 2 and 3, Figs 3 and 4). The
11 patients displaying negative beta-tubulin and c-MYC had a statistically significant better
Table 2. Univariate analysis for Event Free Survival (EFS).
Factor Hazard Ratio 95% CI p-value
Sex 1.92 0.97–3.77 0.058
Age 1.23 0.67–1.26 0.48
Comorbidity (yes vs no) 2.16 0.67–6.07 0.14
Tumor Size (T3-4 vs T1-2) 1.23 0.62–2.44 0.53
Nodal involvement (positive vs negative) 2.19 1.02–4.69 0.043
Grading (G3 vs G1-2) 2.04 0.78–5.39 0.14
Vascular invasion 1.07 0.58–1.96 0.83
Neural inﬁltration 1.48 0.76–2.88 0.24
Adjuvant chemotherapy 1.92 0.68–5.40 0.21
c-MYC (IHC score 1+/2+ vs0) 3.05 1.29–7.21 0.011
Tubulin (IHC score 1+/2+ vs0) 3.10 1.16–8.25 0.024
vs: versus; G: grade; IHC: immunohistochemistry.
doi:10.1371/journal.pone.0127908.t002
Table 3. Univariate analysis for Overall Survival (OS).
Factor Hazard Ratio 95% CI p-value
Sex 1.01 0.48–2.12 0.97
Age 2.47 1.19–5.12 0.015
Comorbidity (yes vs no) 1.12 0.46–2.71 0.80
Tumor Size (T3-4 vs T1-2) 1.48 0.66–3.31 0.33
Nodal involvement (positive vs negative) 3.11 1.04–9.31 0.042
Grading (G3 vs G1-2) 7.73 1.01–15.9 0.049
Vascular invasion 1.33 0.68–2.62 0.40
Neural inﬁltration 1.14 0.51–2.53 0.73
Adjuvant chemotherapy 1.65 0.50–5.41 0.40
c-MYC (IHC score 1+/2+ vs0) 2.94 1.23–7.01 0.015
Tubulin (IHC score 1+/2+ vs0) 2.06 0.89–4.96 0.10
vs: versus; G: grade; IHC: immunohistochemistry.
doi:10.1371/journal.pone.0127908.t003
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2-yrs EFS and OS than those with mixed expression (19 patients) or double positivity (11 pa-
tients) (Figs 4 and 5). Results with regard to T-size and nodal involvement are retorted in
Table 4.
Overall 5-yrs DFS and OS were 11.7% and 30.2%, respectively.
Discussion
In our study we conclude that: 1) 37% of patients with urothelial carcinoma in advanced stage
do express c-Myc; 2) c-Myc is a negative prognostic factor, in fact, its expression results in re-
current disease less than 2 years of diagnosis (p = 0.007; 3) the expression of beta-tubulin-3
turns out to be a negative prognostic factor for disease recurrence within 2 years from diagnosis
(p = 0.02); 4) the molecular pathway of co-expression of c-Myc and beta-tubulin-3 stratify the
prognosis of patients with urothelial carcinoma in advanced stage (p = 0.006); 5) c-Myc path-
way deserves further investigation as predictive marker of response to targeted therapies.
The need to focus on urothelial carcinoma in advanced stage arises from the evidence that
this tumor has a poor prognosis in a significant group of patients. The classic morphological
parameters (such as histology, stage, grading, vascular invasion and neural infiltration) actually
show a limit in predicting the survival of these patients. While for some neoplasms originating
from other districts (such as the gastric tract, breast, lung and central nervous system) were
identified molecular pathways useful for the stratification of patients and set of tests measuring
protein or DNA abnormalities, such as Her-2, ALK, or 1p and 19q status [11–13]. Robust and
reproducible biomarkers are not available for personalized management of the patient [3].
Fig 3. Unudjested Kaplan-Meier curves for Event-free Survival (A) and Overall Survival (B) according to c-Myc.
doi:10.1371/journal.pone.0127908.g003
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Some drugs that inhibit the pathway of c-Myc have shown promising results in other can-
cers but have been little studied in bladder urothelial carcinoma [14]. Similarly, spindle poisons
drugs (such as taxanes), which inhibit mitosis by binding tubulin, have not been extensively in-
vestigated in urothelial tumors. For these reasons, we sought to test these markers on formalin-
fixed tissue by immunohistochemical methods in order to reveal any protein expression, prom-
ising after correlation with clinical endpoints, for better prognostic stratification of patients.
Our data show that the stratification of positivity for c-Myc and beta-tubulin-3 is an impor-
tant prognostic factor for DFS; we also propose the use of different expression of these markers
as an indicator for the stratification of patients in clinical trials that take into consider the vali-
dation of the efficacy of drugs inhibiting these markers.
The proto-oncogene c-Myc encodes a transcription factor that allows the cell to start the
cell cycle, through the activation of several genes involved in proliferation [15]. It is often over-
expressed or mutated in many human cancers and it is frequently associated with aggressive
tumor behavior and poor cell differentiation. The renewed interest in the Myc family as a pos-
sible therapeutic target, has been favored by recent genetic studies showing that a temporary
systemic inhibition of this transcription factor has a significant therapeutic effect on different
types of neoplasia [16]. The proteins of the Myc family in fact, contrary to many classic thera-
peutic targets, are not easily replaced by other signaling pathways, often a mechanism at the
basis of a resistance to target therapy. Some studies have investigated the overexpression of c-
Myc protein in urothelial carcinoma showing a significant association between the increase in
Fig 4. Unudjested Kaplan-Meier curves for Event-free Survival (A) and Overall Survival (B) according to beta-3-tubulin.
doi:10.1371/journal.pone.0127908.g004
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the number of gene copies and tumors of advanced stage or high grade, while little is known
about the possible prognostic value of c-Myc [17–19].
Our work highlights a positive expression of c-Myc in 37% of patients and a statistically sig-
nificant correlation between its expression levels and 2-yr DFS, which results reduced in cases
with positive expression. These results may provide the rationale to identify at molecular level
patients with poorer prognosis eligible for clinical trials with c-Myc pathway inhibitors.
Tubulin is a globular protein which is the fundamental unit of the structures of the cytoskel-
eton called microtubules. It is present in the cytoplasm in the form of dimer α / β. In particular,
the beta-tubulin-3 was proposed as a possible biomarker predictive of response to taxanes. In
fact, some studies argue that overexpression of beta-tubulin-3 may be a common mechanism
of resistance to many advanced solid tumors [20–22]. The predictive and prognostic role of
beta-tubulin isotypes expression in urothelial bladder carcinoma has been recently evaluated,
suggesting an interesting association between high beta-1-tubulin, beta-2-tubulin, beta-tubu-
lin-3 expressions and unfavourable clinico-pathologic factors (like tumour grade and stage),
and shorter recurrence-free survival [23].
The results of this study highlight the existence of a statistically significant correlation between
the expression of beta-tubulin-3 and the 2-yr DFS, thus patients with primary tumors were nega-
tive for this protein in disease-free survival times greater than the positive counterpart. It has not
been possible to evaluate the correlation between the expression levels of beta-tubulin-3 and the
response to taxanes as in our cases only 5 patients were subjected to a treatment with these drugs
Fig 5. Unudjested Kaplan-Meier curves for Event-free Survival (A) and Overall Survival (B) according to the combination of c-Myc and beta-
3-tubulin.
doi:10.1371/journal.pone.0127908.g005
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and, of these, only one patient in the forefront while for others it was a second or even third line,
often without the ability to complete therapy for the arrival of death.
Finally, another important aspect is that all aforementioned molecules may be also tested on
tissue from biopsies.
The combination of different molecular pathways arise from the need to constantly improve
prognostic stratification. Emerging diagnostic tools show that single biomarkers may not be
sufficient to display the biological behaviors [24]. Easy techniques available in routine practice
such as the immunohistochemical analysis permit the combination of double staining such as
those nuclear (i.e. c-Myc) and cytoplasmic (i.e. beta-tubulin-3) markers per single reaction.
Being beta-tubulin-3 a prognostic biomarker and the c-Myc pathway a potential innovative
tool for new generation targeted therapy, we highlight from our study these two molecules be
promising for additional translational research.
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Table 4. Outcome results according to tumor size and nodal involvement.
Beta-tubulin DFS (2-yrs) p-value OS (3-yrs) p-value
T 1–2 Negative n.e. n.e. n.e. n.e.
Positive n.e. n.e.
T 3–4 Negative 41.7 0.13 40.0 0.38
Positive 15.7 12.6
Node-negative Negative 66.7 0.05 40.0 0.32
Positive 12.5 0.0
Node-positive Negative 20.8 0.98 40.0 0.77
Positive 20.6 14.0
c-MYC DFS (2-yrs) p-value OS (3-yrs) p-value
T 1–2 Negative 33.3 n.e. n.e. n.e.
Positive n.e. n.e.
T 3–4 Negative 34.5 0.07 34.5 0.07
Positive 0.0 0.0
Node-negative Negative 33.8 0.72 50.0 n.e
Positive 0.0 n.e.
Node-positive Negative 26.0 0.79 31.8 0.90
Positive 0.0 0.0
DFS: disease free survival; OS: overall survival; yrs: years; n.e.: not evaluable (too few patients).
doi:10.1371/journal.pone.0127908.t004
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